Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05872204 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer

Study acronym: ALEPRO
StatusRecruiting
PhasePhase 2
Started2023-11-30
View on ClinicalTrials.gov ↗

Amendment history

2026-04-28
Study Status v7
Re-verified, no change to tracked fields
2025-03-14
Study Identification, Study Status, Contacts/Locations v6
Primary completion date2026-10→2028-01
Completion date2026-10→2028-01
Study sitescontacts updated at 12 of 12 sites
Study titlerevised
Abemaciclib and Letrozole in Patients withWith Estrogen Receptor-positive Rare Ovarian Cancer
2025-02-26
Study Identification, Study Status, Contacts/Locations v5
Study sitesdetails revised at 12 of 12 sites
Study titlerevised
Abemaciclib and Letrozole in Patients Withwith Estrogen Receptor-positive Rare Ovarian Cancer
2024-06-27
Study Status v4
Re-verified, no change to tracked fields
2024-02-09
Study Status, Contacts/Locations v3
Study sites3→12
Show 2 earlier versions
2023-12-06
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2023-11→confirmed 2023-11-30
Study sitesdetails revised at 3 of 3 sites
2023-06-29
Study Status, Sponsor/Collaborators v1
Collaborators2 to 3 entries
European Network of Gynaecological Oncological Trial Groups (ENGOT)
2023-05-12
Original filing
The purpose of this study is to assess the efficacy and safety of abemaciclib and letrozole for treatment of estrogen receptor-positive rare ovarian cancer.
Trial Details
NCT Number NCT05872204
Lead Sponsor Universitaire Ziekenhuizen KU Leuven
Collaborators: Kom Op Tegen Kanker, Eli Lilly and Company, European Network of Gynaecological Oncological Trial Groups (ENGOT)
Conditions Low Grade Serous Ovarian Carcinoma, Adult Type Granulosa Cell Tumor
Enrollment 100 participants
Start Date 2023-11-30
Primary Completion 2028-01 (estimated)
Study Completion 2028-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-05